Eurocine Vaccines : Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate

As communicated earlier, Eurocine Vaccines is conducting preclinical trials to evaluate the mRNA and protein technology platforms for its therapeutic Herpes simplex virus type 2, HSV-2, vaccine... | December 20, 2022

Related Keywords

Sweden ,Swedish ,Karl Ljungberg ,Preclinical Development At Eurocine Vaccines ,Eurocine Vaccines ,Preclinical Development ,Eurocine Vaccines Ab Publ Stock Exchange ,News ,Information ,Press Release ,Us ,Communicated ,Eurocine ,Vaccines ,Conducting ,Reclinical ,Trials ,O ,Valuate ,The ,Rna ,End ,Protein ,Technology ,Platforms ,Or ,Its ,Herapeutic ,Herpes ,Simplex ,Virus ,Ype Euci Se0015382155 ,